1-(5-Chloropyridin-3-YL)-N-methylmethanamine | 179873-21-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(5-Chloropyridin-3-YL)-N-methylmethanamine
• 英文别名: 1-(5-chloropyridin-3-yl)-N-methylmethanamine
• CAS: 179873-21-3
• 化学式: C₇H₉ClN₂
• 分子量: 156.61
• InChiKey: BKFQGIFXRIVBJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE TYROSINE PHOSPHATASE DE FAIBLE POIDS MOLÉCULAIRE (LMPTP) ET LEURS UTILISATIONS
  申请人：SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST

  公开号：WO2021003398A1

  公开（公告）日：2021-01-07

  Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of LMPTP, compositions, and methods of using these compounds and compositions.

  蛋白酪氨酸磷酸酶（PTPs）是代谢和胰岛素信号传导的关键调节因子。作为胰岛素信号传导的负调节因子，低分子量蛋白酪氨酸磷酸酶（LMPTP）是胰岛素抵抗和相关疾病的靶点。本文描述了能够调节LMPTP活性水平的化合物、组合物以及使用这些化合物和组合物的方法。
• CCR2 MODULATORS
  申请人：ChemoCentryx, Inc.

  公开号：EP3297438B1

  公开（公告）日：2021-10-20
• SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS
  申请人：CHEMOCENTRYX, INC.

  公开号：US20180086756A1

  公开（公告）日：2018-03-29

  Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
• US9783540B2
  申请人：——

  公开号：US9783540B2

  公开（公告）日：2017-10-10
• [EN] METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS<br/>[FR] PROCÉDÉS DE TRAITEMENT DE TUMEURS SOLIDES AU MOYEN D'ANTAGONISTES DU CCR2
  申请人：CHEMOCENTRYX INC

  公开号：WO2019136368A2

  公开（公告）日：2019-07-11

  The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula (I).